杭州华东医药集团新药研究院

Hangzhou Huadong Medicine Group New Drug Research Institute serves as the core innovation engine for Huadong Medicine, one of China's leading pharmaceutical enterprises. The institute focuses on the discovery and clinical development of novel therapeutics across four primary pillars: oncology, endocrinology, immunology, and nephrology. Its robust pipeline includes a diverse array of modalities, ranging from oral small molecule GLP-1 receptor agonists to advanced antibody-drug conjugates (ADCs) and biosimilars. By combining internal R&D capabilities with aggressive global licensing strategies, the institute aims to transition Huadong Medicine from a traditional manufacturer into a global innovation-driven biopharmaceutical player. The institute operates state-of-the-art research facilities in Hangzhou and maintains numerous partnerships with international biotech firms to bring cutting-edge treatments to the Chinese market.